Abstract

Besides their well-documented function of reverse transport of cholesterol, high-density lipoproteins (HDLs) display pleiotropic effects due to their antioxidant, antithrombotic, anti-inflammatory and antiapoptotic properties that may play a
major protective role in acute stroke, in particular by limiting the deleterious
effects of ischaemia on the blood–brain barrier (BBB) and on the parenchymal
cerebral compartment. HDLs may also modulate leukocyte and platelet activa-
tion, which may also represent an important target that would justify the use of
HDL-based therapy in acute stroke. In this review, we will present an update of
all the recent findings in HDL biology that could support a potential clinical use
of HDL therapy in ischaemic stroke.

Keywords
HDL • Ischaemic stroke • Endothelium • Animal models

1 Introduction

Stroke is usually divided according to the type of cerebrovascular lesion into
ischaemic and haemorrhagic stroke. Ischaemia is the leading cause of stroke, due
to obstruction within a blood vessel supplying blood to the brain. It accounts for
about 80–90 % of all stroke cases. Haemorrhagic stroke occurs when a weakened
vessel ruptures due to an aneurysm or arteriovenous malformations. Uncontrolled
hypertension is often associated with haemorrhagic stroke.

Numerous epidemiological studies demonstrate that HDLs are a strong indepen-
dent negative predictor of vascular events (Miller and Miller 1975; Nofer
et al. 2002), supporting HDL-raising therapies. The SPARCL study (Stroke Pre-
vention by Aggressive Reduction in Cholesterol Levels) was designed to assess the
effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or
transient ischaemic attack, but without known coronary heart disease (Amarenco
et al. 2003). In this study, a negative correlation between HDL-C levels and stroke
recurrence was found among these 4,731 patients, but only when ischaemic stroke
was considered. Only baseline HDL-C and LDL/HDL ratio were associated with a
good outcome in the ischaemic stroke subgroup (Amarenco et al. 2009). Each
13.7 mg/dL (0.35 mmol/L) increment in HDL-C was associated with a 13 %
reduction in the risk of ischaemic stroke (Amarenco et al. 2008). Interestingly,
decreased LDL levels and high HDL levels did not have any effect on haemorrhagic
stroke. In a different study, low HDL-C levels have been also associated with a
worse outcome after ischaemic stroke. Of 489 patients treated with rtPA for IS, the
low concentration of HDL-C was also associated with a poor prognosis at 3 months
(Makihara et al. 2012). More recently, another study in patients with atherosclerotic
ischaemic stroke reported that low levels of HDL-C (<35 mg/dL) at admission
were associated with higher stroke severity and poor clinical outcome during
follow-up (Yeh et al. 2013).

Data from studies investigating the effect of HDL subfractions on vascular
prognosis are conflicting, mainly due to the variety of techniques used to assess
HDL particle size (Camont et al. 2011; Krauss 2010). Only the inverse relationship
between large HDLs (alpha1) and vascular risk was found in several studies
(Asztalos et al. 2004; Schaefer and Asztalos 2007; Asztalos and Schaefer 2003). Two large cohorts comprising a total of more than 160,000 people used the Mendelian randomisation single nucleotide polymorphism associated with HDL-C to assess a causative role of HDLs in preventing myocardial infarction (Voight et al. 2012). The authors found no significant relationship and therefore concluded that HDL-C was not causal in vascular disease but merely a risk marker. Another interpretation could be that HDL-C, i.e. cholesterol associated with HDL, is not an appropriate prognostic marker or therapeutic target. Given the pleiotropic functions of HDLs (see below), in particular their protective action on the endothelium (Tran-Dinh et al. 2013), their functionality should be evaluated in addition to the concentration of HDL cholesterol.

The long-term beneficial effect of HDLs has been largely attributed to their role in reverse cholesterol transport and atherosclerotic burden regression. However, short-term HDL elevation has also been shown to be beneficial: in patients with acute coronary syndromes, each 1 mg/dL increment of HDL-C during the course of a 16-week treatment with atorvastatin resulted in a 1.4 % risk reduction for recurrent adverse events (Olsson et al. 2005).

2 Pleiotropic Effects of HDLs

HDLs represent a heterogeneous class of lipoproteins as far as size, shape and composition are concerned. Whereas their principal function is to transport cholesterol from peripheral tissues to the liver, additional functions have been attributed to HDLs, which may depend on their composition in lipids, proteins, vitamins or antioxidant molecules. In this review, we will focus on pleiotropic effects of HDLs other than reverse transport of cholesterol that can impact on stroke at different levels and particularly on ischaemic stroke.

3 HDL Potential Effects on the Blood–Brain Barrier

The blood–brain barrier (BBB) is composed of endothelial cells interconnected by means of tight junctions lining the microvasculature of the central nervous system (CNS), pericytes, astrocytes, end feet and neuron processes. The first barrier separating the blood and cerebral compartments is represented by endothelial cells, which play a pivotal role in regulating the traffic of molecules and blood cells. Many protective properties of HDLs have been documented in endothelial cells (Tran-Dinh et al. 2013) and are developed below, including vasodilatation, antioxidant, anti-inflammatory and antiapoptotic effects. However, most of the in vitro results have been obtained using HUVECs (human umbilical vein endothelial cells) or BAEC (bovine aortic endothelial cells), which do not present the same characteristics as endothelial cells composing the BBB, in terms of permeability and establishment of tight junctions. In this review, we will summarise the different effects attributed to HDLs that could support their use as therapeutic tools in acute
3.1 Reconstituted HDLs and HDL Mimetics

Apo A-1 is the major protein of HDLs, able to recruit lipids and organise HDL particles. Reconstituted HDLs consist of an in vitro combination of apo A-I and phospholipids, producing disc-shaped particles resembling nascent HDL. Apo A-I may be either purified from human plasma or produced by recombinant technology. Carriers of the apo A-I Milano mutation, characterised by the replacement of an arginine by a cysteine at position 173, have reduced plasma levels of apo A-I and HDL-C without increased cardiovascular disease (Sirtori et al. 2001). This observation has led to a strong interest in using apo A-I Milano peptides or proteins as potential therapeutic agent to treat cardiovascular disease (Nissen et al. 2003). Intravenous injection of apo A-I Milano in humans was shown to reduce the atheromatous plaque volume in both murine models and in humans.

However, controversial data have been published as to whether apo A-I Milano is more effective than apo A-I in reverse transporting cholesterol. In mice, gene transfer of wild-type human apo A-I and human apo A-I Milano inhibited the progression of native atherosclerosis and allograft vasculopathy to a similar extent. An equivalent increase in endothelial progenitor cell (EPC) number/function and endothelial regeneration in allografts was also observed (Feng et al. 2009). The use of either native or mutated apo A-I may however be beneficial for endothelial protection and repair in pathological situations such as ischaemic stroke.

The lipid-binding activity of apo A-1 was attempted to be mimicked by synthetic peptides containing the class A amphipathic helix modified by phenylalanine residues on the hydrophobic face. Improvement of the apo A-1 mimetic peptide stability was reached by using D-amino acids instead of L-amino acids which are more readily degraded in plasma. For example, D4F was shown to reduce atherosclerotic lesions in apo E-null mice (Navab et al. 2005) and to improve the anti-inflammatory properties of HDL in humans (Bloedon et al. 2008). Very few data are currently available on the potential beneficial effects, in stroke, of reconstituted HDLs containing wild-type or mutated apo A-I.

4 Part 1: Pleiotropic Effects of HDLs—In Vitro and In Vivo Data

4.1 HDLs and Nitric Oxide (NO)

Hypertension represents a major risk factor for stroke, and polymorphisms governing endothelial NO synthase (NOS3) gene expression/function have been reported to increase the risk of stroke (Berger et al. 2007; Howard et al. 2005). A
recent meta-analysis indicates that NOS3 gene 4b/a, T-786C and G894T polymorphism could be associated with IS (Wang et al. 2013). NO may participate in neuroprotection in cerebral ischaemia by its vasodilatory effects but also by increasing erythrocyte membrane fluidity which could limit the microviscosity (Tsuda et al. 2000). In experimental stroke, administration of NO appears to reduce the infarct volume in both permanent and transient models (Willmot et al. 2005). The results of ongoing clinical studies using NO donors are needed to validate experimental data (Sare et al. 2009). Several lines of evidence suggest that HDLs increase NO bioavailability, in particular via the induction of NOS3 [increased expression and activity (Mineo et al. 2006)]. NO exerts many beneficial effects on the microvasculature during reperfusion including vasodilatation, reflow and decreased permeability (Schulz et al. 2004). The results of the trial “Efficacy of Nitric Oxide in Stroke” are still not available. This study should give more insight into the effects of the glyceryl trinitrate patch (transdermal diffusion of NO) on the outcome post-stroke (ENOS Trial Investigators, 2006).

4.2 HDLs and Sphingosine 1-Phosphate

Sphingosine 1-Phosphate (S1P) is an important lipid component identified in HDLs (Kimura et al. 2001) that may account for NO-mediated vasodilatory effects of HDLs (Nofer et al. 2004). S1P is secreted by activated platelets (Yatomi et al. 1995) but mainly transported in plasma by HDL particles (54 %) (Argraves et al. 2008).

HDLs, and in particular S1P, were demonstrated to directly protect the heart against ischaemia/reperfusion in a mouse model (Theilmeier et al. 2006). The authors report that this protection could be attributed to inhibition of neutrophil recruitment and cardiomyocyte apoptosis in the infarcted area by a mechanism involving NO and S1P signalling.

S1P has been shown to promote endothelial barrier function in cultured pulmonary endothelial cells (Garcia et al. 2001) by enhancing tight junction formation [in HUVECs (Lee et al. 2006)] and cortical actin assembly (Garcia et al. 2001), resulting in a decreased permeability. HDL-associated S1P was also reported to promote endothelial motility, a process of potential importance in case of vascular injury, via Gi-coupled S1P receptors and the Akt signalling pathway (in HUVECs (Argraves et al. 2008)).

In a model of transient middle cerebral artery occlusion in rats, an agonist or the S1P receptor 1 was shown to be neuroprotective, after intraperitoneal injection at the time of reperfusion (Hasegawa et al. 2010). Most studies using this agonist (fingolimod or FTY720) report reduced infarct volumes and improved functional outcomes, as summarised in a recent meta-analysis (Liu et al. 2013). This protective effect could be due to a reduced cerebral lymphocyte infiltration (Rolland et al. 2013). In a thromboembolic model, FTY720 was reported to reduce rtPA-associated haemorrhagic transformations (Campos et al. 2013). Since HDL particles are the major transporter of S1P, it could be expected that at least part of their beneficial effect on the BBB could be attributed to this sphingolipid.
4.3 **Antioxidative Stress**

In stroke, a plethora of studies have shown that oxidative stress is associated with ischaemia and reperfusion and still more so after rtPA treatment. Many experimental studies report that antioxidant treatment displays neuroprotective effects (Margaill et al. 2005). However, hitherto, no concluding clinical study could provide evidence of a potential benefit of antioxidant therapy in stroke (Amaro and Chamorro 2011).

Antiatherogenic functions of HDLs have been related, at least in part, to their antioxidant properties. HDLs contain lipid-soluble vitamins, antioxidants and enzymes such as paraoxonase 1 (PON1), platelet-activating factor acetylhydrolase (PAF-AH) and glutathione phospholipid peroxidase (Florentin et al. 2008). Apo A-I and apo A-II also display antioxidant properties. This antioxidant arsenal confers to HDLs the capacity to limit LDL oxidation and to scavenge lipid hydroperoxides (Navab et al. 2000; Negre-Salvayre et al. 2006). In a rat model of renal ischaemia/reperfusion, rHDLs were shown to reduce the severity of acute ischaemic renal failure associated with decreased malondialdehyde, suggesting attenuation of lipid peroxidation subsequent to oxidative stress (Thiemermann et al. 2003).

4.4 **Anti-inflammatory and Antiprotease Properties**

Acute stroke is characterised by an activated endothelium favouring the recruitment of leukocytes. In particular, neutrophil proteases such as elastase and matrix metalloprotease-9 may induce BBB breakdown and produce deleterious effects on the parenchymal compartment (Stowe et al. 2009). Proinflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) and IL-6 are increased in plasma of patients with acute stroke (Tuttolomondo et al. 2008).

HDLs may exert anti-inflammatory effects on the endothelium but also on leukocytes. In endothelial cells, HDLs (both native and rHDLs) inhibited TNFα and IL-1 induction of leukocyte adhesion molecules VCAM-1, ICAM-1 and E-selectin but had no effect on the expression of platelet endothelial cell adhesion molecule (PECAM) (Cockerill et al. 1995). More recently, McGrath and colleagues reported that the modulatory effects of rHDL on endothelial cells stimulated TNF-alpha and were mediated by DHCR24, an antioxidant enzyme involved in cholesterol biosynthesis (McGrath et al. 2009). Reconstituted HDLs were also reported to limit PMN adhesion to endothelial cells stimulated by TNFα and LPS (Moudry et al. 1997). These effects were later confirmed in vitro using both native and rHDL on HUVECs but also in vivo, in a rat model of haemorrhagic shock (Cockerill et al. 2001). In monocytes, HDL reduced activation of CD11b induced by PMA leading to decreased adhesion to an endothelial cell monolayer, monocytic spreading under shear flow, and transmigration. This process was mimicked by apo A-1 and reported to be ABCA1-dependent (Murphy et al. 2008). More recently, the same group reported that plasma HDLs were potent inhibitors of neutrophil activation both in vitro and in vivo, using mice models of inflammation (Murphy
et al. 2011). In patients with peripheral vascular disease treated by rHDL, they showed a decreased expression of CD11b by neutrophils 5–7 days post-injection versus saline-injected patients. HDLs can also neutralise circulating inflammatory molecules such as C-reactive protein (Wadham et al. 2004) and LPS (Wurfel et al. 1994).

In addition, proteomic studies have shown that HDLs may transport different antiproteases (Karlsson et al. 2005; Vaisar et al. 2007) and in particular alpha-1 antitrypsin (AAT), the natural inhibitor of elastase (Ortiz-Munoz et al. 2009). HDLs displayed antielastase activity and protected vascular cells against elastase-induced apoptosis. Using an in vitro model of BBB (Weksler et al. 2005), we have recently reported that HDLs could limit the deleterious, elastase-mediated role of activated neutrophils under oxygen-glucose deprivation conditions leading to BBB disruption (Bao Dang et al. 2013). In stroke, inhibition of neutrophil elastase may be a therapeutic target, as shown by using specific inhibitors (Ikegame et al. 2010).

4.5 Endothelial Cell Integrity, EPCs and Antiapoptotic Action

Apoptosis is an important mechanism involved in BBB breakdown and associated cerebral damage. In vivo imaging of apoptotic cells using annexin V was reported to be correlated with BBB permeability in patients with acute stroke (Lorberboym et al. 2006). Prevention of apoptosis of all cells composing the neurovascular unit is therefore of major importance to reduce deleterious effects of ischaemia. Plasma HDL-C and apo A-I were reported to prevent apoptosis of endothelial cells induced by mildly oxidised LDL independently of paraoxonase activity (Suc et al. 1997). In this in vitro model (bovine and human endothelial cell lines), HDL binding was specific (receptor-mediated) and HDLs blocked the intracellular calcium increase preceding apoptosis (Escargueil-Blanc et al. 1997). It was suggested that the Apo A-I moiety mediates this cytoprotective effect rather than SP1 (de Souza et al. 2010).

Hypoxia has been reported to induce an autophagic process in endothelial cells (Zhang et al. 2011). Autophagy can be regarded as an adaptive response of the cell to deleterious environmental conditions that could delay apoptosis but could also represent an early step of the apoptotic process. HDLs were shown to inhibit endoplasmic reticulum stress and autophagic response induced by oxidised LDLs in endothelial cells (Muller et al. 2011), suggesting that they impact on very early events of the apoptotic cascade. In the brain, autophagy was significantly increased in the cortex immediately following experimental subarachnoid haemorrhage (SAH) (Lee et al. 2009). During SAH, the BBB is disrupted subsequent to endothelial cell death by apoptosis. In this model, inhibition of apoptosis was shown to significantly reduce the formation of cerebral oedema and associated mortality (Yan et al. 2011). HDLs could thus modulate apoptosis of BBB endothelial cells by preventing autophagy.

Endothelial cell progenitor (EPC) therapy has been envisaged as a potential therapy in stroke [for review, see (Rouhl et al. 2008)]. EPCs can repair damaged vessels and form new ones that could promote recovery after ischaemic injury. In a
mouse model of transient middle cerebral artery occlusion (tMCAO), systemic delivery of EPCs limited brain damage associated with ischemic injury (i.e. improved neurovascular repair and long-term neurobehavioral outcomes) (Fan et al. 2010). In rats, EPCs injected 24 h after tMCAO were shown to reach the injured area and improved functional recovery, potentially attributable to antiapoptotic factors secreted by EPCs (Moubarik et al. 2011). In humans, erythropoietin therapy significantly increased the number of circulating EPCs and improved a 90-day major adverse neurological effect (Yip et al. 2011). Different studies report that reconstituted HDLs may increase circulating EPC number (Tso et al. 2006) and their differentiation from mononuclear cells as well as their angiogenic capacity (Sumi et al. 2007). This was shown in mouse models of endothelial injury in response to LPS and hind limb ischemia but also in humans after injection of rHDLs in type 2 diabetic patients (van Oostrom et al. 2007). This increase in circulating EPCs was significant at day 7 post-injection. In hypercholesterolemic subjects, HDL concentration was linked to EPC number and function (Rossi et al. 2010). Low EPC number was also reported to be an independent risk factor for endothelial dysfunction in these patients. Petoumenos et al. reported a correlation between circulating EPCs and HDL concentrations in patients with coronary artery disease (Petoumenos et al. 2009). In addition, they have shown that recombinant HDLs improved the function of circulating EPCs in a model of endothelial denudation, which could be one explanation for the vasculoprotective actions of HDLs.

4.6 Antithrombotic Actions

In stroke, haemostasis disorders are associated with dysfunction of vascular endothelium, or with abnormalities of or interference with anticoagulant proteins (i.e. protein C, protein S and antithrombin III) (Coull and Clark 1993). However, all factors favouring clot formation may increase the risk of ischemic stroke, involving all cellular components (endothelium, erythrocytes, platelets and leukocytes).

HDLs may modulate haemostasis by impacting on platelet, red blood cell (RBC) and endothelial functions (Mineo et al. 2006). For example, thrombin-induced endothelial tissue factor expression in vitro was shown to be downregulated by rHDLs (Viswambharan et al. 2004). Since tissue factor induction on endothelial cells is regulated by NO production, HDLs may inhibit its production in response to endotoxins or cytokines, by increasing the synthesis of NO (Yang and Loscalzo 2000).

Apo A-I, its amphipathic peptide analogues and HDLs were also shown to protect erythrocytes against the generation of procoagulant activity (Epand et al. 1994). HDL₂ subfraction was reported to be inversely correlated with erythrocyte aggregation in hypercholesterolemic patients (Razavian et al. 1994). A multiple regression analysis demonstrated that this association was independent of fibrinogen, the major determinant of erythrocyte aggregation. The mechanisms
by which HDL-2 may prevent RBC aggregability have not been elucidated, but this
effect is relevant in small-sized arteries where increased blood viscosity may trigger
clot formation. Apo A-I, its amphipathic peptide analogues and HDLs were also
shown to protect erythrocytes against the generation of procoagulant activity
(Epand et al. 1994). HDLs may inhibit phospholipid flip-flop and the associated
procoagulant activity. In healthy volunteers receiving low doses of LPS, injection
of rHDLs reduced collagen-induced platelet aggregation and modified the
procoagulant state associated with endotoxemia (Pajkrt et al. 1997). More recently,
reconstituted HDL infusion in patients with type 2 diabetes induced a 50–75 %
attenuation of platelet aggregation in response to ADP and collagen (Calkin
et al. 2009). In vitro, this effect was shown to be dose-dependent and remained
after removal of rHDLs. Ex vivo, under blood flow conditions, rHDL limited
thrombus formation on a matrix of collagen. This effect was attributed to the
phospholipid moiety of rHDLs, since it was not reproduced by apo A-I, whereas
phosphatidylcholine reached the same level of reduction of aggregation as intact
rHDLs. However, in this study, plasma HDLs did not display similar in vitro effects
on platelet aggregation. The authors suggest that this may be due to limited efflux of
cholesterol from platelet membranes induced by native HDLs.

5 HDLs in the Cerebral Compartment

5.1 Lipoproteins in the Brain

Various studies have described the capacity of the brain to synthesise lipoproteins
that are different from plasma lipoproteins (for review, see Wang and Eckel 2014).
Lipoproteins found in the cerebrospinal fluid (CSF) mainly originate from
astrocytes and are characterised by a small size (resembling the size and density
of HDLs) and contain mainly apo E (Ladu et al. 2000; Koch et al. 2001). Apo E, J,
D and A-I are the main apolipoproteins synthesised in the brain, in an age-dependent
manner for apo J and E (Elliott et al. 2010). Apo E and more particularly apo J are
thought to be involved in the clearance of amyloid β-peptide by astrocytes and
microglial cells (Mulder et al. 2014; Calero et al. 2000). Most of lipoproteins
isolated from the CSF are associated with amyloid β-peptide and may participate
in its polymerisation, transport and clearance (Ladu et al. 2000). The BBB requires
a local homeostasis of cholesterol. Whereas astrocytes are thought to be the major
lipoprotein factory, neurons may also participate in the regulation of their synthesis
and redistribution in the brain (Pfrieger and Ungerer 2011). After cortical spreading
depression (a stimulus that provides long-lasting ischaemic tolerance), apo J
expression is increased, suggesting that this apolipoprotein may participate in
neuroprotection subsequently to an ischaemic episode (Wiggins et al. 2003). In a
model of middle cerebral artery occlusion, apo J-deficient mice displayed a worse
structural restoration in the vicinity of the infarct scar as compared to WT mice
(Imhof et al. 2006).
5.2 Plasma HDLs in the Brain

Under physiological conditions, it is not clear whether HDLs reach the cerebral parenchymal compartment. Based on in vitro results using bovine cerebral endothelial cells, HDLs have been suggested to cross the BBB via paracellular transport (de Vries et al. 1995). More recent data describe an active process of transcytosis involving receptors for HDLs at the surface of endothelial cells. In particular, SRB1 seems to be involved in HDL uptake whereas ABCA1 (ATP-binding cassette transporter A1) is responsible for internalisation of apo A-1 alone (for review, see von Eckardstein and Rohrer 2009). However, most studies on transendothelial transport of HDLs were performed on aortic endothelial cells that may differ from endothelial cells of the BBB. Few studies are available on HDL actions on neurons and astrocytes. Ferretti et al. reported that HDLs reduced oxidative stress and cell death induced by copper ions in rat astrocytes (Ferretti et al. 2003). In rat type I astrocytes and glioma cells, HDLs stimulated DNA synthesis and expression of fibroblast growth factor-2, a potent neurotrophic factor, which was associated with the activation of proliferative intracellular signalling (Malchinkhuu et al. 2003). It is likely that in pathological conditions (haemorrhage or transient increase of BBB permeability), HDLs have an improved access to the cerebral parenchymal compartment and then act on both neurons and astrocytes (Lapergue et al. 2010, 2013).

6 Part 2: HDLs and Acute Stroke (In Vivo Data)

Under acute stroke conditions, the lipid profile has been reported to be modified (Santos-Silva et al. 2002). These authors have shown that patients with diagnosed ischaemic stroke (CT imaging, \( n = 21 \)) had lower plasma concentrations of both HDL and apo A-I than healthy subjects with no history of cardiovascular events and normal haematologic values \( (n = 29) \). Blood was sampled after a 12-h fasting period. In these patients, leukocyte count was increased relative to controls, but the concentration of granulocytes accounted for most of this increase (monocytes were moderately augmented whereas lymphocyte count was decreased in stroke patients). More importantly, markers of neutrophil activation, including lactoferrin and elastase, were strongly increased in plasma of stroke patients when compared to controls.

6.1 HDLs and Acute Stroke: Experimental Models

Few studies have attempted to use HDL therapy in acute stroke. Based on the observation that low HDL cholesterol levels were associated with cerebrovascular events (Sacco et al. 2001; Wannamethee et al. 2000), Paterno et al. showed that pretreatment with reconstituted HDL reduced neuronal damage in two experimental models of stroke in rats (Paterno et al. 2004). They showed that high doses of
rHDLs (120 mg/kg) infused 2 h before the onset of stroke reduced the brain necrotic area by 61 and 76 %, respectively, in an excitotoxic (NMDA) and a transient MCAO model of stroke in rats. More recently, we have shown that plasma HDLs (10 mg/kg), injected immediately or at 3 or 5 h after stroke, also reduced cerebral infarct volume by 74, 68 and 70 %, respectively, in a rat model of thromboembolic stroke (Lapergue et al. 2010). This was associated with a reduced BBB breakdown and decreased neutrophil recruitment in the infarct area. In this model, injection of fluorescent-labelled HDLs showed a staining of endothelial cells (but also glial cells), suggesting that their primary protective effect was on the BBB. Thus, HDLs may be a powerful neuroprotective tool for the treatment of cerebrovascular diseases by preventing BBB breakdown. We have confirmed these in vivo results by a study using a model of BBB in vitro (Bao Dang et al. 2013).

In humans, recombinant tissue plasminogen activator (rtPA) is the only effective fibrinolytic treatment in ischaemic stroke. The disruption of the BBB is involved in oedema and haemorrhagic transformation following tPA treatment. We assessed whether HDL-rtPA combined treatment could improve the safety and efficacy of tPA in experimental stroke. We showed that HDL injection decreased tPA-induced haemorrhagic transformation in two models of focal middle cerebral artery occlusion (MCAO) (embolic and 4-h monofilament MCAO). Both the blood–brain barrier in vitro model and in vivo results support the vasculoprotective action of HDLs on BBB under ischaemic conditions. Finally, HDLs do not interfere with the fibrinolytic activity of rtPA (Lapergue et al. 2013).

**Conclusion**

In addition to reverse transport of cholesterol, HDL particles display different protective effects that could support their use in the acute phase of stroke. Different neuroprotective drugs proven to be effective in animal models have failed to translate into clinical settings (Xu and Pan 2013). Early treatments that could be used without interfering with fibrinolytic treatments should be considered as a good option to limit the deleterious effects of ischaemic stroke. HDLs may represent a good candidate, particularly with respect to their protective effects on the endothelium in ischaemia/reperfusion conditions. As discussed by Navab et al., HDL mimetic peptides should be more appropriate for use in chronic settings since they can be administrated orally or by subcutaneous route, whereas reconstituted HDLs may be more suitable for acute treatment by intravenous injection (Navab et al. 2010). Whether apo A-I combined with phospholipids are sufficient to prevent the effects of ischaemia is questionable. It is likely that enrichment of reconstituted HDLs with protective molecules such as antioxidants or antiproteases should provide an optimal beneficial effect as observed when using plasma HDLs isolated from healthy subjects in different animal models of stroke.

**Acknowledgements** OM’s group at Inserm is supported by the Fondation de France, the Fondation Coeur et Artères and the Agence Nationale de la Recherche (ANR JCJC 2010).
Open Access  This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References


Moudry R, Spycher MO, Doran JE (1997) Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 7(3):175–181


